Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2019  |  Volume : 15  |  Issue : 5  |  Page : 961--970

Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors


Rygiel Katarzyna1, Bulas Lucyna2 
1 Department of Family Practice, Medical University of Silesia (SUM), Katowice-Zabrze, Zabrze, Poland
2 Department of Pharmacy, Medical University of Silesia (SUM), Katowice, Poland

Correspondence Address:
Rygiel Katarzyna
Department of Family Practice, Medical University of Silesia (SUM), Katowice-Zabrze; 3 Maja St.13/15, 41-800 Zabrze
Poland

Epigenomics is the study of the gene expression changes due to epigenetic processes and not due to the deoxyribonucleic acid (DNA) base sequence alterations. The key mechanisms of epigenetic regulation include DNA methylation, histone modifications, and noncoding RNAs. Epigenetic alterations in cancer are predominantly linked with hypermethylation of promoters of the tumor suppressor genes, global DNA hypomethylation, and increased expression of histone deacetylases (HDAC). There is a growing need to investigate epigenetic patterns and to provide safe and effective, innovative therapeutic strategies for oncology patients, who did not improve on traditional anticancer regimens. The epi-drugs (e.g., DNA methyltransferase inhibitors, e.g., azacitidine and decitabine and HDAC inhibitors, e.g., vorinostat and romidepsin) have been approved for the clinical use. In this paper, we provide a brief overview of the mechanisms of action and targets for novel epi-drugs, focusing on their potential clinical applications in patients with solid tumors, resistant to standard oncology treatments.


How to cite this article:
Katarzyna R, Lucyna B. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.J Can Res Ther 2019;15:961-970


How to cite this URL:
Katarzyna R, Lucyna B. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors. J Can Res Ther [serial online] 2019 [cited 2019 Nov 22 ];15:961-970
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2019;volume=15;issue=5;spage=961;epage=970;aulast=Katarzyna;type=0